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ABSTRACT 
Objectives: To assess reliability of a novel objective outcome measure, Laser Doppler imaging 
(LDI), its validity against skin biopsy histology, and other clinical instruments including 
Localised Cutaneous Lupus Disease Area and Severity Index (L-CLASI), Visual Analogue 
Scale (VAS) score of photographs and its responsiveness to clinical change with therapy.  
Methods: A prospective observational cohort study was conducted in 30 active CLE patients. 
At baseline and 3 months, disease activity was assessed using L-CLASI and a high resolution 
LDI system by two assessors. Skin biopsy was scored as 0=non-active, 1=mild activity and 
2=active. Photographs were assessed by two clinicians using 100mm VAS. Inter-rater 
reliability was analysed using Bland-Altman limits of agreement. Correlation between 
histology and LDI, L-CLASI and VAS and sensitivity to change of LDI with physician 
subjective assessment of change (PSAC) at 3 months were anaO\VHGXVLQJ.HQGDOO¶VWDX-a. 
Results: Of 30 patients with CLE, 28 (93%) were female, mean (SD) age 48.4 (11.5) years, 25 
(83%) were Caucasians, 25 (83%) had concurrent SLE and 16 (53%) were smokers. CLE 
subtypes were acute=9, subacute=8 and chronic=13. Inter-rater agreement for LDI was fair but 
for VAS score of photographs was poor. In 20 patients with biopsy, correlation with histology 
was better for LDI (tau-a=0.56) than L-CLASI [0.26; difference 0.27 (90% CI 0.05, 0.49)] or 
VAS score of photographs [0.17; 0.36 (0.04, 0.68)]. There was a moderate correlation between 
PSAC score and change in LDI (tau-a=0.56, 90% CI 0.38, 0.74; p<0.001, n=15). 
Conclusion: LDI provides a reliable, valid and responsive quantitative measure of 
inflammation in CLE. It has a better correlation with histology compared to clinical 
instruments. LDI provides an objective outcome measure for clinical trials. 
(274 words)  
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INTRODUCTION 
Cutaneous lupus erythematosus (CLE) comprises a wide of range of dermatologic 
manifestations seen in patients with or without systemic lupus erythematosus (SLE). In general, 
the prognosis of isolated CLE is considered more favourable than SLE but it may evolve into 
SLE in about 20% of the patients 1. CLE can be divided into LE-specific lesions i.e. Acute 
Cutaneous LE (ACLE), Subacute Cutaneous LE (SCLE) and Chronic Cutaneous LE (CCLE) 
and LE-nonspecific skin lesions (e.g. vasculitis) 2. Deposition of immune complexes containing 
IgM, IgG and complement C3 at the dermo-epidermal junction is pathognomonic in the former. 
However, not all CLE is driven by B-cell dysfunction 3. There is also a markedly greater 
increase in Type I interferon (IFN-I) activity in the skin compared to blood, which precedes 
onset of clinical symptoms 4. 
Given this immunological heterogeneity, it is not surprising that responses to therapy vary. 
Cutaneous response rates to the licensed biologic in SLE are mixed in clinical trials with lower 
numbers of British Isles Lupus Activity Group Disease Activity Index version 2004 (BILAG-
2004) and SLE Disease Activity Index version 2000 (SLEDAI-2K) improvements compared 
to the musculoskeletal domain 5. We previously showed that poor response or worsening could 
be observed in the skin of patients who otherwise responded well to rituximab in other organ 
systems 6. 
Current methods for assessing CLE activity include validated clinical indices such as the CLE 
Disease Area and Severity Index (CLASI) 7 and the revised CLASI 8. For SLE, specific 
assessment for mucocutaneous components are included in the BILAG-2004 9 and SLEDAI-
2K 10. However, these indices depend on the physicianV¶MXGJHPHQW and if each symptom is 
due to active CLE, damage or another disease. They also require adequate training and may be 
complex for inexperienced clinicians to use. SLEDAI-2K cannot capture partial response to 
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therapy or differentiate mild, moderate or severe disease 11. The BILAG has a more limited 
ability to capture partial response, since a wide range of severity and change in the skin fall 
within the BILAG B rating, and improvement relies on the assessors¶ ability to recall previous 
appearances. These instruments were developed to document activity in the whole body rather 
than localised lesions. Thus, validated, objective, quantitative outcome measures are needed. 
These would allow us to more sensitively detect improvements with therapy, and to compare 
the different targeted therapies proposed, with less influence by expertise and recall of the 
assessors. 
Microcirculatory abnormalities contribute to the pathophysiology of many autoimmune 
rheumatic diseases including CLE 12. Accordingly, various therapies target this and have 
pharmacologic effect on skin microcirculation 13, 14. High Resolution Laser Doppler imaging 
(LDI) is a single-probe, non-invasive imaging modality that monitors the total local 
microcirculatory blood perfusion including the perfusion in capillaries, arterioles, venules and 
shunting vessels EDVHGRQDSKHQRPHQRQNQRZQDVWKH³'RSSOHUHIIHFW´15. LDI has been used 
to assess responsiveness after pharmacological stimuli in patients wLWK5D\QDXG¶VSKHQRPHQRQ
16
. Alteration in peripheral blood flow (as measured by LDI) has been shown to correlate with 
inflammation in skin psoriasis 17. Nevertheless, LDI has not previously been investigated in 
CLE or cutaneous manifestations of SLE. 
The objectives of this study were to assess the reliability of LDI, its criterion and construct 
validity and responsiveness to clinical change with therapy, with a view to providing a tool that 
can objectively document response to therapies in clinical trials. 
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METHODS 
Design and Patients 
A prospective observational cohort study was undertaken in consecutive patients with active 
CLE in Leeds, UK between October 2014 and October 2017. Inclusion criteria were (i) adults 
18 years old); (ii) active CLE as dHILQHG E\ &/$6,4; and (iii) underwent a change in 
therapy either increment in dosage or commencement on new immunosuppressive therapies. 
Ethical Approval  
All patients provided informed written consent and this research was carried out in compliance 
with the Declaration of Helsinki. All research activities were performed under ethical approval, 
REC 10/H1306/88, National Research Ethics Committee Yorkshire and Humber±Leeds East, 
UK. The University of Leeds was contracted with administrative sponsorship.  Written consent 
to publication of photographs from the patients were obtained using Leeds Teaching Hospitals 
NHS Trust consent form.  
Demographic and laboratory assessment 
The following demographic and clinical parameters were recorded: age, gender, ethnicity, 
smoking history, concurrent diagnosis of SLE and concomitant therapies including 
corticosteroid.  
Anti-nuclear antibody (ANA) and a panel of nuclear autoantibodies including anti-dsDNA and 
extract nuclear antigens (ENAs, including Ro52, Ro60, La, Sm, Chromatin, RNP, Sm/RNP 
and Ribosomal P) were tested using Bioplex 2200 Immunoassay. Complement levels (C3 and 
C4) were measured by nephelometry. 
Clinical assessment  
All patients were assessed in a combined rheumatology±dermatology connective tissue disease 
clinic at baseline and 3 months post-treatment. The Gilliam classification was used by 
 7 
consultant dermatologists to grade CLE as ACLE, SCLE, CCLE and non-specific LE (e.g. 
vasculitis) 2. 
Physician outcome measures  
CLE disease activity was initially assessed using CLASI to determine eligibility for inclusion 
into the study. Since only one area with the highest CLASI score was assessed using the LDI, 
a modified Localised CLASI (L-CLASI), 18 which consists of the sum of erythema and 
scaling/hypertrophy scores of the selected area, with a maximum total score possible of 5 was 
used for assessment and analysis.  
At 3 months, the Physician Subjective Assessment of Change (PSAC) 19 was used by a 
dermatologist (independent of L-CLASI scoring) to grade changes in activity as worsening, 
unchanged or improved since the last visit WKH SK\VLFLDQ¶V VXEMHFWLYH assessment of the 
SDWLHQW¶VVNin disease.  
Digital Photographs Score 
Digital photographs of the CLE lesions were taken using a macro digital camera, Canon EOS 
600D during pre- and post-treatment. These were assessed by a dermatologist and a 
rheumatologist who were blinded to SDWLHQWV¶ clinical status and sequence. Both clinicians rated 
the overall CLE disease activity using a visual analogue scale (VAS) of 100mm; where 0=very 
good and asymptomatic and 100=very poor and severe symptoms. The two raters then provided 
the agreed scores for each photograph. Significant discrepancies were resolved by consensus. 
Dermatology Life Quality Index 
The patients completed the Dermatology Life Quality Index (DLQI) at baseline. This 
instrument consists of 10 questions concerning the impact of CLE on different aspects of their 
health related quality of life over the last week. Each question was scored on a 4-point Likert 
scale as follows: Not at all/Not relevant=0, A little=1, A lot=2 and Very much=3. Scores of 
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individual items (0-3) are added to yield a total score (0-30); higher scores represent greater 
impairmeQWRISDWLHQW¶VTXDOLW\RIOLIH 20. 
Laser Doppler Imaging 
An area with the highest L-CLASI score and non-lesional area were evaluated using a high 
resolution LDI system (moorLDI2-IR, Moor Instruments UK) by either a medical physicist or 
a rheumatologist; both trained in the operation of LDI and EOLQGHGWRSDWLHQWV¶ L-CLASI scores. 
For some patients, the scans were performed by both operators (within 15 minutes apart) to 
assess inter-rater reliability. All scans were performed in a designated assessment room after 
the patients were acclimatised in room temperature (23º Celcius) for 15 minutes. Images were 
acquired at a distance between 40-70 cm depending on the size of the selected region, using a 
bandwidth between 250Hz-15KHz and the scan speed of < 4ms/pixel. The region of interests 
(ROIs) were selected and analysed using Moor LDI2-IR v6.0 software. Typical scan 
resolutions were set to 170 x 100 pixels but were adjusted to ensure that imaging times were 
below 2 minutes or less in order to minimise movement artefacts. Gain was set to zero to avoid 
signal saturation. Appropriate health and safety precautions were taken when using the LDI 
scanner. 
The absolute difference in the mean perfusion between active and non-active CLE lesions was 
calculated and expressed in perfusion unit (PU). PU is an arbitrary unit, which is proportional 
to the product of the average speed of the RBCs and their concentrations. 
Skin Biopsy Score 
Skin biopsy samples obtained from the consenting patients were rated in real-time by a 
KLVWRSDWKRORJLVWZLWKRYHU\HDUV¶H[SHULHQFHLQUHSRUWLQJ&/(FDVHVand blinGHGWRSDWLHQWV¶ 
clinic status. Since there was no standardised scoring system, the biopsy was scored based on 
the six classic features of CLE 21, 22 including (i) interface dermatitis; (ii) inflammatory cell 
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infiltrate in a perivascular, periappendageal or subepidermal location; (iii) vacuolar alteration 
of the basal layer; (iv) thickening of the basement membrane; (v) follicular plugging and (vi) 
the presence of immunofluorescence. The first two parameters were rated using a graded scale 
of 0-2; 0=absent, 1=mild and 2=strong while the remaining four parameters using a binary 
scale; 0=absent, 1=present, with a maximum total score possible of 8. Since these parameters 
were not weighted for clinical importance, an overall histology grade was assigned using a 
graded scale of 0-2; 0=non active, 1=mild and 2=active.  
Statistical Analysis 
Descriptive statistics were summarised using either mean with SD or median with IQR for 
continuous variables and proportion for categorical variables. Agreement of the VAS score of 
photographs between the dermatologist and rheumatologist and inter-reader reliability of the 
LDI were analysed using Bland-Altman limits of agreement (LOA). The gold standard 
reference was the overall histology grade. For criterion and construct validity, correlation 
between the LDI parameter and overall histology grade as well as other outcome measures i.e. 
L-CLASI and VAS score of photographs were analysed XVLQJ.HQGDOO¶VWau-a. This test was 
also used to assess sensitivity to change of the LDI and expressed in terms of mean difference 
versus average and 90% confidence interval (CI). 90% CI was chosen to obtain a narrower 
interval due to sample size and the exploratory nature of this research. Correlation between the 
two continuous variables, LDI and DLQI was assessed using Pearson correlation coefficient.  
All statistical analysis was performed using Stata v.13.1 (StataCorp College Station, Texas, 
USA) for Windows and Graph Pad Prism v.8.0 (GraphPad, La Jolla, CA, USA). 
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RESULTS 
Patient and treatment characteristics 
30 patients with active CLE were recruited into the study. Of these, 28 (93%) were female, 
mean (SD) age 48.4 (11.5) years, 25 (83%) were Caucasians, 25 (83%) had concurrent SLE 
and 16 (53%) were smokers. The proportions of CLE subtypes were ACLE=30%, SCLE=27% 
and CCLE=43%. Baseline characteristics are described in Table 1. 
Inter-rater agreement for VAS score of photographs  
There was a poor agreement in VAS score of digital photographs between the two assessors; 
mean difference -9.5 mm (90% CI LOA -36.2 to 17.3) versus average (Figure 1A). 
Inter-rater agreement for LDI 
In the 7 patients where the LDI measurements were independently assessed by two assessors, 
inter-reader reliability of LDI was fair; mean difference 11.5 PU (90% CI LOA -61.6 to 84.5) 
versus average (Figure 1B).  
Validity of LDI against histology, L-CLASI and VAS score of photographs 
Skin biopsies were performed in 20/30 patients. Of these, correlation with histology was better 
for LDI (tau-a=0.53, 90% CI 0.35-0.72; p<0.001) than L-CLASI [tau-a= 0.26 (0.06-0.46); 
p=0.036, difference LDI vs L-CLASI 0.27 (90% CI 0.05-0.49)] or VAS score of photographs 
[tau-a=0.17 (-0.07 ± 0.40); p=0.223, difference LDI vs VAS 0.36 (0.04-0.68)] (Figure 2A). 
Three patients who were mimickers of active CLE indeed had negative histology and low PU 
using LDI. Examples of images of two patients with active CLE symptoms; each with and 
without positive histology are illustrated in Figures 3 and 4 respectively. 
Relationship between LDI and DLQI 
22/30 patients completed DLQI at baseline visit. Mean (SD) DLQI at baseline was 14.7 (8.1). 
There was a moderate correlation between LDI and DLQI, r = 0.515; p=0.014.  
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Clinical response to therapy 
15/30 patients had a follow-up at 3 months following a change in therapy. Of these, the 
proportions of patients who improved, unchanged and worsening based on PSAC score were 
7 (47%), 3 (20%) and 5 (33%) respectively. There was a trend to improvement at 3 months 
using the various therapies employed to treat CLE based on L-CLASI score, mean difference 
pre- and post-treatment 0.73 (95% CI -0.06 to 1.53); p=0.068. Details of therapies and 
responses are described in Table 2.  
Responsiveness to clinical change with therapy between PSAC score and LDI 
The percentage change from baseline between pre- and post-treatment perfusion difference in 
LDI was calculated. There was a moderate correlation in sensitivity to change between PSAC 
score and the LDI (tau-a=0.56, 90% CI 0.38-0.74; p<0.001). This relationship is depicted in 
Figure 2B. 
DISCUSSION 
This report presents data on the use of a novel objective outcome measure, LDI in assessing 
disease activity in various CLE morphologies. We show that LDI appears to be reliable, 
correlates better with the gold standard reference, the overall histology grade, compared to 
other clinical indices and is sensitive to change with therapy. 
CLE is heterogeneous in term of its pathophysiology. Recent advances have demonstrated the 
role of keratinocytes and endothelial cells in perpetuating inflammation by expressing adhesion 
molecules in response to ultraviolet light or other stimuli 23. Since measurement of endothelial 
activities are not routinely available, a logical approach is to quantify microvascular blood flow 
to the inflamed skin, which can be achieved using LDI. Other advantages of LDI include its 
convenience and non-invasiveness i.e. non-contact compared to a skin biopsy. Indeed, in other 
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autoimmune skin diseases like psoriasis, changes in LDI outperformed the expression level of 
CD31, a marker of endothelial activity in active psoriasis plaques 24.  
Current CLE disease activity indices such as the CLASI 7 and RCLASI 8 were developed to 
document activity in the whole body rather than localised lesions.  The overall CLASI or 
RCLASI scores may not be a true representative of the intensity of the activity in localised 
lesions. Modified limited versions of these indices could be used to assess these lesions but 
they have not been validated. LDI overcomes this by providing quantitative measures of 
individual CLE lesions. Moreover, the distribution of CLE lesions is often more localised than 
generalised as well as less systemic 25. Despite this, these individual lesions can be difficult to 
treat and most importantly, DIIHFWSDWLHQWV¶VHOI-esteem and quality of life 26. This is especially 
relevant in cutaneous or systemic lupus since lesions commonly occur on visible areas of the 
skin such as the face, neck and scalp. Thus, by quantifying the degree of inflammation 
objectively using LDI, this will guide the clinicians to tailor the intensity of therapy 
accordingly. Furthermore, in order to minimise toxicity from systemic therapies, various 
topical 18, 27 and intra-dermal route of drug delivery 28 are currently used and in development 
to target these individual lesions. Thus, LDI is an ideal tool to document responsiveness to 
these therapies objectively and can delineate the problem with subjectivity in the assessments 
of change between pre- and post-treatment.   
Although the CLASI has been validated and is widely used, another limitation of this index is 
the element of training-dependent subjectivity in differentiating active disease, damage and 
non-inflammatory pathologies. There is also potential for bias by incorporating patient-
reported symptoms in the score (i.e. recent hair loss within the last 30 days, and duration of 
dyspigmentation after active lesions have resolved 7) with total scores being adjusted based on 
these verbal reports. We found the inter-rater agreement in VAS score of photographs was 
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poor, which could be contributed to inability to detect salient morphology like hypertrophy of 
CLE through photo images. On the other hand, although one may argue that LDI may be 
operator-dependent, the inter-rater reliability between a medical physicist and a rheumatologist 
was fair in this study. The apparent wide confidence interval shown has to be interpreted in the 
context of a wide range of possible PU values, ranging from 0 to 1500.  
This study has some limitations. First, the number of patients available to assess responsiveness 
to change using LDI was too small (n=15) to calculate the optimal threshold of changes in LDI 
against the magnitude of improvement by PSAC. However, we had shown that the percentage 
change in LDI parameter and PSAC score was moderately correlated. Next, although LDI was 
correlated with DLQI at baseline, its minimal clinically important difference post-treatment 
could not be estimated due to the sample size. Lastly, LDI was performed in selected areas 
with the highest CLASI score for patients although many had generalised CLE. This may limit 
the validity of measurement of response in widespread disease where responses may differ 
between body areas. However, for topical therapies or early phase assessment of novel systemic 
therapies, assessment of a selected target lesion has been used successfully. Further studies 
would be needed to explore its use in patients with generalised CLE, the feasibility of capturing 
multiple images throughout the body with respect to resources and tolerability as well as flare 
prediction in areas with high PU value but clinically asymptomatic. 
In conclusion, LDI provides a reliable, valid quantitative measure of inflammation in CLE and 
appears to be responsive to change with therapy.  LDI has a better correlation with histology 
compared to currently available clinical instruments. Further validation and longitudinal 
analysis will provide evidence on its usefulness in clinical trials and quantitative assessment of 
treatment response. 
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FIGURE LEGENDS: 
Figure 1: Inter-rater agreement of VAS score of photographs and LDI. Both graphs 
display a scatter diagram of the differences plotted against the averages of the two 
measurements. Horizontal lines are drawn at the mean difference (blue), and at the limits of 
agreement (green). A) There was a poor agreement of VAS score of photographs using the 
100mm scale between the two raters. B) The agreement for LDI between the two assessors was 
fair. LDI: Laser Doppler imaging, PU: perfusion unit, VAS: visual analogue scale 
 
Figure 2: Criterion and construct validity of LDI and its responsiveness to change with 
therapy. A) Of 20 patients with skin biopsy, correlation with histology was better for LDI than 
L-CLASI and VAS score of photographs. The bars represent box and whiskers plots while the 
error bars denote tukey. B) Of 15 patients with a follow-up at 3 months, the change in perfusion 
unit of LDI between baseline and 3 months corresponded to PSAC score. L-CLASI: modified 
localised cutaneous lupus disease area and severity index, LDI: Laser Doppler imaging, PSAC: 
physician subjective assessment of change, PU: perfusion unit, VAS: visual analogue scale 
 
Figure 3: LDI images of a patient with clinically active CLE, positive histology and high 
PU. Her L-CLASI score was 3 (Erythema=2, Scale/Hypertrophy=1). ROIs 1-3 denote active 
lesions while 4-5 represent non-lesional areas. Absolute difference was calculated by 
subtracting non-lesional with the smallest ROI from active lesion with the largest ROI. PU: 
perfusion unit, ROI: region of interest 
 
Figure 4: LDI images of a patient perceived clinically active CLE but with negative 
histology and low PU.  Her L-CLASI score was 2 (Erythema=1, Scale/Hypertrophy=1). ROIs 
1, 4 and 5 denote clinically active lesions while 2-3 represent non-lesional areas. PU: perfusion 
unit, ROI: region of interest 
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Table 1: Baseline characteristics of the 30 patients with active CLE 
Characteristics Values 
Age, years; mean (SD) 48.4 (11.5) 
Female; N (%) 28 (93) 
Ethnicity; N (%) 
     Caucasian 
     Indian/South Asian 
 
25 (83) 
  5 (17) 
Diagnosis; N (%) 
     Systemic lupus erythematosus 
     Cutaneous lupus erythematosus only 
 
25 (83) 
  5 (17) 
Type of cutaneous lupus erythematosus; N (%) 
     Acute cutaneous lupus erythematosus 
     Sub-acute cutaneous lupus erythematosus 
     Chronic cutaneous lupus erythematosus 
 
  9 (30) 
  8 (27) 
13 (43) 
Positive ANA at Baseline assessment; N (%) 25 (83) 
Positive ANA specificities; N (%) 
     anti-dsDNA  
     anti-Ro  
     anti-La  
     anti-Smith  
     anti-Chromatin  
     anti-RNP  
     anti-Ribosomal P 
 
  3 (10) 
16 (53) 
  6 (20) 
  4 (13) 
  9 (30) 
  4 (13) 
  1 (3) 
Low complement levels (C3 or C4); N (%)   2 (7) 
Ever smoked; N (%) 16 (53) 
Concomitant immunosuppressant; N (%) 
    Anti-malarials 
    Methotrexate 
    Mycophenolate Mofetil 
    Abatacept 
    Belimumab 
 
20 (67) 
  4 (13) 
11 (37) 
  1 (3) 
  1 (3) 
 20 
Characteristics Values 
    Rituximab 
    Other investigational drugs 
  7 (23) 
  4 (13) 
Location of Index CLE lesion for assessment; N (%) 
    Scalp 
    Face  
    Neck 
    Arms 
    Back 
 
8 (27) 
9 (30) 
3 (10) 
4 (13) 
6 (20) 
 
ANA: Anti-nuclear antibody, CLE: cutaneous lupus erythematosus, dsDNA: Double stranded 
deoxyribonucleic acid, LDI: Laser Doppler imaging, RNP: Ribonucleic protein. 
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Table 2: Details of treatment prescribed for CLE and response 
ID CLE subtype Conventional or 
Biological Disease 
Modifying Anti-
Rheumatic Drugs 
Pre-Treatment 
 
Post-Treatment PSAC score 
L-CLASI Absolute 
Difference in 
LDI (PU) 
L-CLASI Absolute 
Difference in 
LDI (PU) 
Percentage 
change 
from 
baseline in 
LDI (%) 
1 CCLE Belimumab 3 704.3 5 1072.8 -52.3 Worsening 
2 CCLE Investigational Drug 4 580.5 4 735.6 -26.7 Worsening 
3 ACLE HCQ, MMF 4 221.6 2 508.0 -129.2 Worsening 
4 CCLE HCQ 4 120.0 4 246.3 -105.3 Worsening 
5 SCLE HCQ, MMF, RTX 2 321.2 5 608.8 -89.5 Worsening 
6 CCLE HCQ,MMF 3 533.9 4 600.5 -12.5 No change 
7 CCLE MTX 4 874.8 4 397.6 54.6 No change 
8 SCLE HCQ, MTX 3 10.9 1 14.1 -29.4 No change 
9 CCLE Investigational Drug 5 732.0 3 228.6 68.8 Improved 
10 CCLE Investigational Drug 4 640.8 2 415.5 35.2 Improved 
11 SCLE HCQ, MMF 2 242.4 1 213.6 11.9 Improved 
12 CCLE RTX 3 259.3 1 144.9 44.1 Improved 
13 CCLE HCQ 3 380.0 2 85.3 77.6 Improved 
14 CCLE HCQ 3 351.3 2 170.0 51.6 Improved 
15 ACLE HCQ, MMF, RTX 2 301.9 0 176.8 41.4 Improved 
 
ACLE: acute cutaneous lupus erythematosus, CCLE: chronic cutaneous lupus erythematosus, HCQ: hydroxychloroquine, L-CLASI: modified 
localised cutaneous lupus disease area and severity index, LDI: Laser Doppler imaging, MMF: mycophenolate mofetil, MTX: methotrexate, RTX: 
rituximab, PSAC: physician subjective assessment of change, PU: perfusion unit, SCLE: sub-acute cutaneous lupus erythematosus 
 
